TEMo Gene signatures for breast cancer diagnosis


The presence of cancer causes changes to the immune system. A 13-gene signature characteristic of the presence of breast cancer has been identified from blood samples, and a diagnostic to identify this signature as a means of detecting breast cancer more effectively than existing methods has been developed.

Bile duct cancer is difficult to detect

APPLICATION

Early diagnosis of patients with suspected cancer

Diagnostic test for breast cancer

DEVELOPMENT STATUS

Pilot scale development

IP STATUS

Priority application
UK Patent Application No 1702392.0

COMMERCIAL OFFERING

Development and/or licensing partners required.

OPPORTUNITY


In the UK there are 300,000 cancer diagnoses each year, and a quarter of all deaths are cancer related. Early diagnosis saves lives – 90% of women diagnosed with early stage breast cancer survive for at least five years. However, current diagnostic tests such as mammography have limited efficacy, and over-diagnosis results in unnecessary treatments and a waste of resources. For other cancer types, such as ovarian, current tests are inadequate for early diagnosis. As such, there is a need for improved diagnostic tests.

TECHNOLOGY


Cancer cells ‘distract and educate’ the immune system to promote their own growth. Our researchers have utilised this phenomenon to identify aa 13-gene signature for breast cancer. A simple, blood-based diagnostic test is being developed to determine the presence of this signature, and therefore diagnose breast cancer more effectively than existing methods. Similar gene signatures for other cancers are also being identified.

The diagnostic detected breast cancer in a test set with 92.54% accuracy, 94% specificity and 91.79% sensitivity. Similar results are seen in test groups with different ethnic compositions, indicating the test to be robust. By comparison, mammography has 78% accuracy and 84% sensitivity.

BENEFITS


  • Better patient outcomes, and reduced waste of resources on unnecessary procedures
  • Non-invasive, and no unnecessary scans required, reducing radiation exposure
  • Technology identifying signatures for other cancer types
  • The market for cancer diagnostics is valuable and growing rapidly

Please note, header image is purely illustrative.

Source: pexels-pixabay-CC0 & iStock© (c)shutterstock

Enquiry for: TEMo Gene signatures for breast cancer diagnosis

10 + 3 =